Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Hospira

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

- PMLiVE

Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer

The combination was approved in the US last month to treat BRAF V600E-mutant disease

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer in the UK every year

- PMLiVE

Amgen’s Imdylltra approved by MHRA to treat small cell lung cancer in adults

SCLC accounts for approximately 15% of all lung cancer diagnoses and progresses rapidly

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

- PMLiVE

Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer

The disease is the third most common type of cancer globally

- PMLiVE

Amgen’s Blincyto granted MHRA approval for new acute lymphoblastic leukaemia indication

Approximately 300 new adult cases of the blood cancer are diagnosed in the UK every year

- PMLiVE

Amgen announces $1bn investment to establish new US drug manufacturing facility

The expansion in North Carolina builds on the company’s previous $550m commitment in the area

- PMLiVE

Novartis gains rights to PTC’s Huntington’s programme in deal worth up to $2.9bn

The genetic disorder affects one in every 10,000 to 20,000 people in the US

- PMLiVE

Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

The company has announced a phase 3 programme across obesity and related conditions

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links